Last reviewed · How we verify

Lymphostat B (BELIMUMAB)

Human Genome Sciences Inc. · FDA-approved approved Monoclonal antibody Quality 59/100

Belimumab works by blocking the B Lymphocyte Stimulator, a protein that can contribute to the autoimmune response in Systemic lupus erythematosus.

Lymphostat B, also known as Belimumab, is a B Lymphocyte Stimulator-specific Inhibitor developed by Human Genome Sciences Inc. It targets the Tumor necrosis factor ligand superfamily member 13B and is used to treat Systemic lupus erythematosus. Belimumab is a small molecule modality that was FDA approved in 2011. It is currently owned by Human Genome Sciences Inc. and its commercial status is patented.

At a glance

Generic nameBELIMUMAB
SponsorHuman Genome Sciences Inc.
Drug classB Lymphocyte Stimulator-specific Inhibitor [EPC]
TargetTumor necrosis factor ligand superfamily member 13B
ModalityMonoclonal antibody
Therapeutic areaOncology
PhaseFDA-approved
First approval2011
Annual revenue1100

Mechanism of action

BENLYSTA is BLyS-specific inhibitor that blocks the binding of soluble BLyS, B-cell survival factor, to its receptors on cells. BENLYSTA does not bind cells directly, but by binding BLyS, BENLYSTA inhibits the survival of cells, including autoreactive cells, and reduces the differentiation of cells into immunoglobulin-producing plasma cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: